Core Viewpoint - BioNTech SE will announce its financial results for the second quarter of 2025 on August 4, 2025, and will host a conference call and webcast for stakeholders to discuss these results and provide a corporate update [1]. Group 1: Financial Results Announcement - The financial results for Q2 2025 will be disclosed on August 4, 2025 [1]. - A conference call and webcast will take place at 8:00 a.m. EDT (2:00 p.m. CEST) on the same day [1]. Group 2: Accessing the Conference Call - Participants can register for the live conference call via a provided link, with dial-in numbers and a PIN sent post-registration [2]. - It is recommended to register at least one day in advance for the call [2]. - The slide presentation and audio of the webcast will be accessible through a specified link [2]. Group 3: Company Overview - BioNTech is a global next-generation immunotherapy company focused on developing novel therapies for cancer and serious diseases [4]. - The company utilizes a variety of computational discovery and therapeutic modalities for rapid biopharmaceutical development [4]. - BioNTech's oncology product candidates include mRNA cancer immunotherapies, immunomodulators, and targeted therapies such as antibody-drug conjugates and CAR T cell therapies [4]. - The company is also developing multiple mRNA vaccine candidates for infectious diseases alongside its oncology pipeline [4]. - BioNTech has established collaborations with various global pharmaceutical companies, including Bristol Myers Squibb, Pfizer, and Genentech [4].

SOUTH SAN FRANCISCO, Calif., July 21, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the upcoming investor relations event. 2025 BTIG Virtual Biotechnology Conference Tuesday, July 29th, 2025 at 4:40 PM ET Fireside chat with Yujiro S. Hata, President and Chief Executive Officer, hosted by Justin Zelin, Director, Biotechnology Research Analyst A live audio w ...

但随着其3年累计亏损超过50亿元人民币、一系列法律纠纷及客户集中度加剧等问题浮出水面，外界对 其上市前景和长期可持续性打上了问号。 近期，特斯联智慧科技股份有限公司（下称"特斯联"）再次向港交所递交更新招股书，试图敲开资本市 场的大门。这家自称"全球领先平台型AIoT服务商"的企业，正寻求通过香港上市为其持续亏损的业务 输血。 尽管特斯联的营收不断攀升，但其盈利能力一直未见起色。2022年、2023年和2024年，公司分别录得净 亏损23.87亿元、8.03亿元和21亿元，三年累计亏损超过50亿元。 | | | | 低于17月21日正十段 | | | | | --- | --- | --- | --- | --- | --- | --- | | | 2022年 | | 2023年 | | 2024年 | | | | 人民幣 | కొ | 人民幣 | રા | 人民管 | 100 | | | | | (人民幣千元,百分比除外) | | | | | 收入 | 738,288 | 100.0 | 1,006,248 | 100.0 | 1.843.099 | 100.0 | | 销售成本 .. | (663,712 ...

Meet India’s Self-Made Biologics Brewmaster Billionaire https://t.co/eQOzaAOKOf https://t.co/eQOzaAOKOf ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Sarepta Therapeutics due to allegations of violations of federal securities laws related to misleading statements about the safety of its product ELEVIDYS [3][5]. Company Overview - Sarepta Therapeutics, Inc. is a biotechnology company focused on developing therapies for rare diseases, particularly those related to genetic disorders [3]. Legal Proceedings - A federal securities class action has been filed against Sarepta, with a deadline of August 25, 2025, for investors to seek the role of lead plaintiff [3][12]. - The complaint alleges that Sarepta and its executives made false or misleading statements regarding the safety of ELEVIDYS, which posed significant risks to patients [5]. Product Safety Issues - On March 18, 2025, Sarepta reported a patient death following treatment with ELEVIDYS, leading to a stock price drop of $27.81 per share, or 27.44%, closing at $73.54 [6]. - Following regulatory scrutiny, Sarepta halted recruitment and dosing in some ELEVIDYS clinical studies on April 4, 2025, resulting in a further stock price decline of $4.18 per share, or 7.13%, to close at $54.43 [7][8]. - A second patient death due to acute liver failure was disclosed on June 15, 2025, prompting Sarepta to suspend shipments of ELEVIDYS for non-ambulatory patients and pause dosing in one clinical study, causing a significant stock price drop of $15.24 per share, or 42.12%, to close at $20.91 [9][10]. - The FDA issued a Safety Communication on June 24, 2025, regarding the investigation into the risk of acute liver failure associated with ELEVIDYS, leading to an additional stock price decline of $1.52 per share, or 8.01%, to close at $17.46 [10][11]. Investor Communication - Faruqi & Faruqi encourages investors who suffered losses in Sarepta to contact them for discussions about their legal rights and options [1][13].

A decade ago, shares of Exelixis (EXEL -0.91%), a biotech company specializing in oncology, were trading for under $10 per share. Today, the drugmaker's shares are changing hands for about $45 apiece. In other words, Exelixis has crushed the market since 2015.Some might think there is little upside left for the stock after this run, but that's not the case. Read on to find out why Exelixis still has plenty of growth fuel left in the tank. Cabometyx is still doing the heavy liftingExelixis is best known for ...

Core Viewpoint - The biotechnology industry presents significant investment opportunities, particularly in pre-revenue companies with high price targets set by analysts, indicating potential for dramatic gains in a short time [1][4]. Group 1: Compass Pathways - Compass Pathways is developing a treatment for depression using synthetic psilocybin, with a current market cap of approximately $363 million, down from a peak of over $2 billion during the COVID-19 pandemic [5][10]. - Analysts have set a consensus price target of $15.78 for Compass Pathways, suggesting a potential gain of over 300% from current prices [5]. - The company reported positive results from the COMP005 trial for treatment-resistant depression (TRD), showing a 3.6-point improvement on the Montgomery-Asberg Depression Rating Scale (MADRS) compared to the placebo group [8][9]. - The upcoming COMP006 study will further evaluate the efficacy of COMP360, with expectations that stronger results could significantly increase the stock's value [10]. Group 2: Viking Therapeutics - Viking Therapeutics, another clinical-stage drugmaker, has seen its market cap drop to approximately $3.6 billion from a peak of over $9 billion, with analysts projecting a price target of $90.26, indicating a potential increase of 181% [12]. - The company's lead candidate, VK2735, has shown promising results in weight loss, achieving a placebo-adjusted weight loss of 13% after 13 weeks of treatment [13]. - Viking Therapeutics is positioned to compete with established products like Zepbound, which generated $9.3 billion in annualized sales in the first quarter of this year [14]. - The company is currently conducting a phase 3 study to support a new drug application, which carries risks if tolerability issues arise [15].

Drugs like Ompic have taken the world by storm. In China, biotech companies are developing dozens of similar drugs that can potentially challenge such medical advances in the US and EU. And these aren't just knockoffs.A new exclusive Bloomberg News analysis shows the country is playing a bigger role in coming up with innovative medicines to treat serious diseases like cancer and cardiovascular conditions. Look at China's growing share of the global drug research. Chinese drug makers are now studying way mor ...

Core Viewpoint - A class action lawsuit has been filed against Capricor Therapeutics, Inc. for allegedly providing misleading information regarding its lead drug candidate, deramiocel, leading to investor losses during the specified class period [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased Capricor securities between October 9, 2024, and July 10, 2025 [1]. - Investors have until September 15, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit [1]. Group 2: Allegations Against Capricor - The complaint alleges that Capricor provided materially misleading information about deramiocel's potential to receive a Biologics License Application (BLA) approval from the FDA [3]. - It is claimed that while making positive statements, Capricor concealed adverse facts regarding the safety and efficacy data from its Phase 2 HOPE-2 trial [3]. Group 3: Impact of FDA Response - On July 11, 2025, Capricor announced it received a Complete Response Letter (CRL) from the FDA, denying the BLA due to insufficient evidence of effectiveness and the need for additional clinical data [4]. - Following the announcement of the CRL, Capricor's stock price fell from $11.40 per share on July 10, 2025, to $7.64 per share on July 11, 2025 [5].

智通财经7月19日讯（编辑 平方）据Choice数据统计显示，剔除新股次新股以及ST股，包括舒泰神、上纬新材、一品红、胜宏科技、昂利康、仕佳光子、新 易盛、益方生物-U、潍柴重机、博瑞医药、亿田智能、奔朗新材、诺诚健华-U、佳合科技、中际旭创、上海洗霸、圣诺生物、东山精密、森林包装、康辰 药业、鼎泰高科、迈威生物-U、沪电股份、景旺电子、泽璟制药-U、应流股份、力鼎光电、信立泰、平安电工、广合科技、焦点科技、生益科技、宏创控 股、中航沈飞、海思科、亚翔集成和博隆技术在内的37家A股上市公司周五盘中创出历史新高（前复权），具体详见下图： 全球环保耐蚀树脂的主要供应商上纬新材周五收盘录得20CM八连板且均是一字板，刷新历史新高至33.47元/股。上纬新材7月8日公告，智元机器人拟至少 收购公司63.62%股份。公开资料显示，智元机器人为国内具身智能头部公司。随后，上纬新材股价开启大幅上涨，期间，上纬新材多次发布异动公告称， 智元机器人股权收购能否完成尚存在不确定性。此外，据蓝鲸新闻7月9日报道，智元机器人否认拟收购上纬新材63.62%股份为借壳上市，并称二者业务协 同方案后续会对外公布。 | | | 周五盘中创历 ...